ADCT compared with FATE: revenue, margins and what each company keeps, and the suppliers and customers both name

ADCTADC Therapeutics SA

Mkt capRevenueRevenue

FATEFate Therapeutics Inc

Mkt capRevenueRevenue

Compare

ADCTADC Therapeutics SA

FATEFate Therapeutics Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ADCT

0 of 2at or beyond implied

Reportimpliedrealized× implied

Nov 5 '26—▼−4.65%—

Oct 13 '26—▼−8.60%—

Q2 FY26±90.3%▼−14.63%×0.16

May 4 '26±23.0%▼−3.92%×0.17

FATE

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q3 FY26—▼−11.48%—

Q2 FY26±20.5%▼−7.35%×0.36

= impliedADCT realized, solidFATE realized, hatchedOne scale, both sides: full bar = 91%× = |realized| ÷ impliedSource: market data

May 13 '26

±57.5%

▼−5.11%

×0.09

Q1 FY26±21.3%▲+5.41%×0.25

ADCTADC Therapeutics SA

1.64· pre 1.60· delayed

Mkt cap$209.4MRevenue$19MQ2 FY26Revenue$71MFY24

FATEFate Therapeutics Inc

1.86· pre 1.81· delayed

Pre-marketNov 5 '26delayed

Mkt cap$224.9MRevenue$2MQ2 FY26Revenue$7MFY25

Compare

Pre-marketNov 5 '26delayed

ADCTADC Therapeutics SA

FATEFate Therapeutics Inc

1.64pre 1.60delayed

Price

1.86pre 1.81delayed

$209.4M

Mkt cap

$224.9M

Q2 FY26$19M

Revenue

$2MQ2 FY26

FY24$71M

Revenue

$7MFY25

ADCT1.64vsFATE1.86Pre-marketNov 5 '26delayed